A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of VIR-2482 for the Prevention of Influenza A Illness
Latest Information Update: 10 Jun 2022
At a glance
- Drugs VIR 2482 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions; First in man
- Sponsors Vir Biotechnology
Most Recent Events
- 08 Jun 2022 Status changed from recruiting to completed.
- 22 Jun 2021 Planned End Date changed from 1 Jan 2022 to 1 Nov 2021.
- 22 Jun 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Nov 2021.